The results are important prerequisites for the design of in vivo biodistribution and imaging studies to further support our hypothesis that radiolabeled Cdk4 inhibitors are suitable radiotracers for tumor imaging by means of PET. This evidence concerns the gene CDK4 and neoplasm.